HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.

Fiche publication

Date publication

mars 2019

Journal

Gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas , Dr DAVIDSON Irwin , Dr HABERSETZER François , Dr LUPBERGER Joachim , Pr PESSAUX Patrick , Dr CROUCHET Emilie

Tous les auteurs :
Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30836093

Résumé

Chronic hepatitis C virus (HCV) infection is an important risk factor for hepatocellular carcinoma (HCC). Despite effective antiviral therapies, the risk for HCC is reduced but not eliminated following a sustained virologic response (SVR) to direct-acting antiviral (DAA) agents, and risk is higher in patients with advanced fibrosis. We investigated HCV-induced epigenetic alterations that might affect risk for HCC after DAA treatment in patients and mice with humanized livers.